Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Navitor Pharmaceuticals
700 Main Street
Cambridge, MA 02139
Phone: 617-863-3693
www.navitorpharma.com

Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company™s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell™s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor™s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company™s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.

Key Contact
Name
George P. Vlasuk
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
06/19/14 $23,500,000 Series A Atlas Venture
Johnson & Johnson Innovation
Polaris Partners
SR One
The Longevity Fund
undisclosed
12/18/15 $33,000,000 Series B Atlas Venture
Brace Pharma
Johnson & Johnson Development Corporation (JJDC)
Polaris Partners
Remeditex Ventures
Sanofi-Genzyme BioVentures
SR One
undisclosed


Featured Reading